Development and deployment of COVID-19 vaccines for those most vulnerable

Ensuring that COVID-19 vaccines are delivered to older populations and those living in low resource settings is essential to end the pandemic. Development of safe and effective COVID-19 vaccines is a global priority and the best hope for ending the COVID-19 pandemic. Remarkably, in less than 1 year, vaccines have been developed and shown to be efficacious and are already being deployed worldwide. Yet, many challenges remain. Immune senescence and comorbidities in aging populations and immune dysregulation in populations living in low-resource settings may impede vaccine effectiveness. Distribution of vaccines among these populations where vaccine access is historically low remains challenging. In this Review, we address these challenges and provide strategies for ensuring that vaccines are developed and deployed for those most vulnerable.

[1]  Bjoern Peters,et al.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.

[2]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[3]  D. Lauffenburger,et al.  Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.

[4]  J. Mascola,et al.  Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination , 2020, The New England journal of medicine.

[5]  J. Bloom,et al.  Prospective mapping of viral mutations that escape antibodies used to treat COVID-19 , 2020, bioRxiv.

[6]  Jon Cohen ‘Absolutely remarkable’: No one who got Moderna’s vaccine in trial developed severe COVID-19 , 2020 .

[7]  Nguyen H. Tran,et al.  Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. , 2020, Lancet.

[8]  K. Chu,et al.  Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial , 2020, The Lancet Infectious Diseases.

[9]  P. Kremsner,et al.  Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers , 2020, medRxiv.

[10]  Marc‐André D'Aoust,et al.  Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants , 2020, medRxiv.

[11]  M. Beltramello,et al.  The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity , 2020, bioRxiv.

[12]  C. Cordon-Cardo,et al.  Robust neutralizing antibodies to SARS-CoV-2 infection persist for months , 2020, Science.

[13]  M. Lipsitch,et al.  Understanding COVID-19 vaccine efficacy , 2020, Science.

[14]  P. Doshi Covid-19 vaccine trial protocols released , 2020, BMJ.

[15]  B. Haynes,et al.  Prospects for a safe COVID-19 vaccine , 2020, Science Translational Medicine.

[16]  E. Walsh,et al.  Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates , 2020, The New England journal of medicine.

[17]  C. Franceschi,et al.  Shelter from the cytokine storm: pitfalls and prospects in the development of SARS-CoV-2 vaccines for an elderly population , 2020, Seminars in Immunopathology.

[18]  J. Nkengasong,et al.  COVID-19 vaccines: how to ensure Africa has access , 2020, Nature.

[19]  V. Gladyshev,et al.  COVID‐19 is an emergent disease of aging , 2020, Aging cell.

[20]  R. Baric,et al.  Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults , 2020, The New England journal of medicine.

[21]  N. Hacohen,et al.  Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity , 2020, Science.

[22]  Steven M. Holland,et al.  Autoantibodies against type I IFNs in patients with life-threatening COVID-19 , 2020, Science.

[23]  Jacques Fellay,et al.  Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 , 2020, Science.

[24]  F. Krammer SARS-CoV-2 vaccines in development , 2020, Nature.

[25]  Lisa E. Gralinski,et al.  Animal models for COVID-19 , 2020, Nature.

[26]  D. Cummings,et al.  A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity , 2020, Nature Communications.

[27]  M. Beltramello,et al.  Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology , 2020, Cell.

[28]  J. Cramer,et al.  Evolution of the COVID-19 vaccine development landscape , 2020, Nature Reviews Drug Discovery.

[29]  A. Gintsburg,et al.  Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia , 2020, The Lancet.

[30]  V. Shinde,et al.  Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine , 2020, The New England journal of medicine.

[31]  Lisa E. Gralinski,et al.  A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures , 2020, Nature.

[32]  Yongli Yang,et al.  Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. , 2020, JAMA.

[33]  Madeleine K. D. Scott,et al.  Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans , 2020, Science.

[34]  J. Diedrich,et al.  Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate , 2020, bioRxiv.

[35]  J. Scott,et al.  Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors , 2020, Science.

[36]  U. Reimer,et al.  SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19 , 2020, Nature.

[37]  D. Weissman,et al.  D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization , 2020, Cell Host & Microbe.

[38]  C. Rice,et al.  Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants , 2020, bioRxiv.

[39]  Y. Hu,et al.  Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial , 2020, The Lancet.

[40]  D. Gilroy,et al.  Aging immunity may exacerbate COVID-19 , 2020, Science.

[41]  J. Mascola,et al.  An mRNA Vaccine against SARS-CoV-2 — Preliminary Report , 2020, The New England journal of medicine.

[42]  Chuan Qin,et al.  Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques , 2020, Science.

[43]  S. Rowland-Jones,et al.  Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus , 2020, Cell.

[44]  Anne M Johnson,et al.  Black, Asian and Minority Ethnic groups in England are at increased risk of death from COVID-19: indirect standardisation of NHS mortality data , 2020, Wellcome open research.

[45]  D. Burton,et al.  Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model , 2020, Science.

[46]  B. Coller,et al.  Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens , 2020, npj Vaccines.

[47]  B. Drolet,et al.  Multivalue ethical framework for fair global allocation of a COVID-19 vaccine , 2020, Journal of Medical Ethics.

[48]  J. Singh The Case for Why Africa Should Host COVID-19 Candidate Vaccine Trials , 2020, The Journal of infectious diseases.

[49]  W. Koff,et al.  The future of vaccine development. , 2020, Vaccine.

[50]  Ilya J. Finkelstein,et al.  Structure-based Design of Prefusion-stabilized SARS-CoV-2 Spikes , 2020, bioRxiv.

[51]  Vineet D. Menachery,et al.  The search for a COVID-19 animal model , 2020, Science.

[52]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[53]  R. Baric,et al.  DNA vaccine protection against SARS-CoV-2 in rhesus macaques , 2020, Science.

[54]  P. Sorger,et al.  SARS-CoV-2 infection protects against rechallenge in rhesus macaques , 2020, Science.

[55]  X. Xie,et al.  Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells , 2020, Cell.

[56]  Jon Cohen U.S. 'Warp Speed' vaccine effort comes out of the shadows. , 2020, Science.

[57]  Christopher Earl,et al.  Preexisting and de novo humoral immunity to SARS-CoV-2 in humans , 2020, Science.

[58]  D. Burton,et al.  Rational Vaccine Design in the Time of COVID-19 , 2020, Cell Host & Microbe.

[59]  M. V. van Breemen,et al.  Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability , 2020, Science.

[60]  John R. Mascola,et al.  A strategic approach to COVID-19 vaccine R&D , 2020, Science.

[61]  H. Yen,et al.  Peer Review File Manuscript Title: Pathogenesis and transmission of SARS-CoV-2 in golden Syrian hamsters , 2020 .

[62]  Barney S. Graham,et al.  Rapid COVID-19 vaccine development , 2020, Science.

[63]  C. Verschoor,et al.  The immune response to influenza in older humans: beyond immune senescence , 2020, Immunity & Ageing.

[64]  M. Hamburg,et al.  The Equitable Distribution of COVID-19 Therapeutics and Vaccines. , 2020, JAMA.

[65]  Anne M Johnson,et al.  Black, Asian and Minority Ethnic groups in England are at increased risk of death from COVID-19: indirect standardisation of NHS mortality data. , 2020, Wellcome open research.

[66]  K. Neuzil,et al.  Which Countries Have Adult Vaccine Programs? A Global Review of National Adult Influenza and Pneumococcal Vaccine Policies , 2020 .

[67]  John K Billington,et al.  Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks , 2020, Health Security.

[68]  Koichi Yuki,et al.  COVID-19 pathophysiology: A review , 2020, Clinical Immunology.

[69]  W. Koff,et al.  Covid-19 and Immunity in Aging Populations - A New Research Agenda. , 2020, The New England journal of medicine.

[70]  T. Kuiken,et al.  Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model , 2020, Science.

[71]  W. Wei,et al.  Presymptomatic Transmission of SARS-CoV-2 — Singapore, January 23–March 16, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[72]  A. Zemla,et al.  Rapid in silico design of antibodies targeting SARS-CoV-2 using machine learning and supercomputing , 2020, bioRxiv.

[73]  Xuetao Cao COVID-19: immunopathology and its implications for therapy , 2020, Nature Reviews Immunology.

[74]  Baoying Huang,et al.  Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2 , 2020, Science.

[75]  W. Koff,et al.  Improving Vaccine-Induced Immunity: Can Baseline Predict Outcome? , 2020, Trends in Immunology.

[76]  Eun-Ha Kim,et al.  Infection and Rapid Transmission of SARS-CoV-2 in Ferrets , 2020, Cell Host & Microbe.

[77]  J. Wu,et al.  Vaccine confidence in the time of COVID-19 , 2020, European Journal of Epidemiology.

[78]  Y. Wen,et al.  Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications , 2020, medRxiv.

[79]  S. Berkley COVID-19 needs a big science approach , 2020, Science.

[80]  Wenling Wang,et al.  Age‐related rhesus macaque models of COVID‐19 , 2020, Animal models and experimental medicine.

[81]  Tao Zhang,et al.  Pangolin homology associated with 2019-nCoV , 2020, bioRxiv.

[82]  Wenling Wang,et al.  The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice , 2020, Nature.

[83]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[84]  E. Arias,et al.  Mortality in the United States, 2018. , 2020, NCHS data brief.

[85]  S. Oh,et al.  Aging and the Immune System: the Impact of Immunosenescence on Viral Infection, Immunity and Vaccine Immunogenicity , 2019, Immune network.

[86]  Phillip M. Muthoka,et al.  The partnership for influenza vaccine introduction (PIVI): Supporting influenza vaccine program development in low and middle-income countries through public-private partnerships , 2019, Vaccine.

[87]  R. Rappuoli,et al.  Vaccines and global health: In search of a sustainable model for vaccine development and delivery , 2019, Science Translational Medicine.

[88]  H. Woodrow,et al.  : A Review of the , 2018 .

[89]  M. Beibel,et al.  TORC1 inhibition enhances immune function and reduces infections in the elderly , 2018, Science Translational Medicine.

[90]  F. Brombacher,et al.  Chronic schistosomiasis suppresses HIV-specific responses to DNA-MVA and MVA-gp140 Env vaccine regimens despite antihelminthic treatment and increases helminth-associated pathology in a mouse model , 2018, PLoS pathogens.

[91]  A. Chit,et al.  Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis , 2018, Expert review of vaccines.

[92]  B. Weinberger Vaccines for the elderly: current use and future challenges , 2018, Immunity & Ageing.

[93]  N. Grassly,et al.  Causes of impaired oral vaccine efficacy in developing countries , 2017, Future microbiology.

[94]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[95]  R. Kennedy,et al.  Personalized vaccinology: A review , 2017, Vaccine.

[96]  S. Plotkin,et al.  The complexity and cost of vaccine manufacturing – An overview , 2017, Vaccine.

[97]  G. Kobinger,et al.  Syrian Hamsters as a Small Animal Model for Emerging Infectious Diseases: Advances in Immunologic Methods , 2016, Advances in experimental medicine and biology.

[98]  J. Yewdell,et al.  Generation and Protective Ability of Influenza Virus-Specific Antibody-Dependent Cellular Cytotoxicity in Humans Elicited by Vaccination, Natural Infection, and Experimental Challenge. , 2016, The Journal of infectious diseases.

[99]  A. Ls,et al.  Unmet need for contraception in developing countries: Examining womens reasons for not using a method. , 2016 .

[100]  A. Pera,et al.  Immunosenescence: Implications for response to infection and vaccination in older people. , 2015, Maturitas.

[101]  K. Subbarao,et al.  Animal models for SARS and MERS coronaviruses , 2015, Current Opinion in Virology.

[102]  G. Kang,et al.  Biological challenges to effective vaccines in the developing world , 2015, Philosophical Transactions of the Royal Society B: Biological Sciences.

[103]  G. Alter,et al.  Beyond adjuvants: Antagonizing inflammation to enhance vaccine immunity. , 2015, Vaccine.

[104]  John Earl,et al.  Efficacy of high-dose versus standard-dose influenza vaccine in older adults. , 2014, The New England journal of medicine.

[105]  J. Singer,et al.  Immune activation alters cellular and humoral responses to yellow fever 17D vaccine. , 2014, The Journal of clinical investigation.

[106]  M. Elizabeth Halloran,et al.  Optimal Vaccine Allocation for the Early Mitigation of Pandemic Influenza , 2013, PLoS Comput. Biol..

[107]  Stephen S. H. Huang,et al.  Differential Pathological and Immune Responses in Newly Weaned Ferrets Are Associated with a Mild Clinical Outcome of Pandemic 2009 H1N1 Infection , 2012, Journal of Virology.

[108]  R. Baric,et al.  Molecular Determinants of Severe Acute Respiratory Syndrome Coronavirus Pathogenesis and Virulence in Young and Aged Mouse Models of Human Disease , 2011, Journal of Virology.

[109]  J. Yewdell,et al.  MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines , 2011, Science Translational Medicine.

[110]  David P. Fidler,et al.  Negotiating Equitable Access to Influenza Vaccines: Global Health Diplomacy and the Controversies Surrounding Avian Influenza H5N1 and Pandemic Influenza H1N1 , 2010, PLoS medicine.

[111]  Tadataka Yamada Poverty, wealth, and access to pandemic influenza vaccines. , 2009, The New England journal of medicine.

[112]  Andrew Pekosz,et al.  An immunosuppressed Syrian golden hamster model for SARS-CoV infection , 2008, Virology.

[113]  D. Weiskopf,et al.  Biology of immune responses to vaccines in elderly persons. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[114]  B. Ni,et al.  Inhibition of severe acute respiratory syndrome-associated coronavirus infection by equine neutralizing antibody in golden Syrian hamsters. , 2007, Viral immunology.

[115]  David K. Meyerholz,et al.  Lethal Infection of K18-hACE2 Mice Infected with Severe Acute Respiratory Syndrome Coronavirus , 2006, Journal of Virology.

[116]  T. Slezak,et al.  Cynomolgus Macaque as an Animal Model for Severe Acute Respiratory Syndrome , 2006, PLoS medicine.

[117]  T. Greenough,et al.  Therapy with a Severe Acute Respiratory Syndrome–Associated Coronavirus–Neutralizing Human Monoclonal Antibody Reduces Disease Severity and Viral Burden in Golden Syrian Hamsters , 2006, The Journal of infectious diseases.

[118]  Cécile Viboud,et al.  Antibody response to influenza vaccination in the elderly: a quantitative review. , 2006, Vaccine.

[119]  B. Murphy,et al.  Severe Acute Respiratory Syndrome Coronavirus Infection of Golden Syrian Hamsters , 2005, Journal of Virology.

[120]  L. Simonsen,et al.  The Japanese experience with vaccinating schoolchildren against influenza. , 2001, The New England journal of medicine.

[121]  A. Mccarthy Development , 1996, Current Opinion in Neurobiology.

[122]  D. Tyrrell,et al.  The time course of the immune response to experimental coronavirus infection of man , 1990, Epidemiology and Infection.

[123]  L. Wilkinson Immunity , 1891, The Lancet.

[124]  Ping Li,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020 .

[125]  Daniel Coppard,et al.  Quantitative Review , 2020, Encyclopedia of Personality and Individual Differences.

[126]  J. Zimmermann Manufacturing: An Overview , 2010 .

[127]  S. Tyring,et al.  Vaccine immunology , 2009, Dermatologic therapy.

[128]  J. Cattell The Future of , 1961 .